Alignment Healthcare, Inc. (ALHC) Stock Competitors & Peer Comparison
See (ALHC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALHC | $23.69 | +1.83% | 4.9B | 264.56 | $0.09 | N/A |
| UNH | $420.41 | +0.14% | 377.3B | 25.42 | $16.34 | +2.16% |
| CVS | $103.49 | -0.09% | 132B | 14.63 | $7.07 | +2.55% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.42% |
| ELV | $394.54 | +1.68% | 84B | 12.56 | $30.78 | +1.77% |
| CI | $277.94 | -0.29% | 72.9B | 8.92 | $30.90 | +2.21% |
| HUM | $401.70 | +3.29% | 47.7B | 25.04 | $15.86 | +0.90% |
| CNC | $66.43 | +2.93% | 31.7B | 25.47 | $2.52 | N/A |
| MOH | $227.55 | -0.87% | 11.9B | 32.94 | $6.92 | N/A |
| OSCR | $30.89 | +4.90% | 7.4B | -48.36 | -$0.59 | N/A |
Stock Comparison
ALHC vs UNH Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, UNH has a market cap of 377.3B. Regarding current trading prices, ALHC is priced at $23.69, while UNH trades at $420.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas UNH's P/E ratio is 25.42. In terms of profitability, ALHC's ROE is +0.11%, compared to UNH's ROE of +0.12%. Regarding short-term risk, ALHC is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check UNH's competition here
ALHC vs CVS Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, CVS has a market cap of 132B. Regarding current trading prices, ALHC is priced at $23.69, while CVS trades at $103.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas CVS's P/E ratio is 14.63. In terms of profitability, ALHC's ROE is +0.11%, compared to CVS's ROE of +0.04%. Regarding short-term risk, ALHC is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check CVS's competition here
ALHC vs ANTM Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, ALHC is priced at $23.69, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas ANTM's P/E ratio is 18.99. In terms of profitability, ALHC's ROE is +0.11%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, ALHC is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check ANTM's competition here
ALHC vs ELV Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, ELV has a market cap of 84B. Regarding current trading prices, ALHC is priced at $23.69, while ELV trades at $394.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas ELV's P/E ratio is 12.56. In terms of profitability, ALHC's ROE is +0.11%, compared to ELV's ROE of +0.12%. Regarding short-term risk, ALHC is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check ELV's competition here
ALHC vs CI Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, CI has a market cap of 72.9B. Regarding current trading prices, ALHC is priced at $23.69, while CI trades at $277.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas CI's P/E ratio is 8.92. In terms of profitability, ALHC's ROE is +0.11%, compared to CI's ROE of +0.15%. Regarding short-term risk, ALHC is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check CI's competition here
ALHC vs HUM Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, HUM has a market cap of 47.7B. Regarding current trading prices, ALHC is priced at $23.69, while HUM trades at $401.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas HUM's P/E ratio is 25.04. In terms of profitability, ALHC's ROE is +0.11%, compared to HUM's ROE of +0.06%. Regarding short-term risk, ALHC is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check HUM's competition here
ALHC vs CNC Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, CNC has a market cap of 31.7B. Regarding current trading prices, ALHC is priced at $23.69, while CNC trades at $66.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas CNC's P/E ratio is 25.47. In terms of profitability, ALHC's ROE is +0.11%, compared to CNC's ROE of -0.29%. Regarding short-term risk, ALHC is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check CNC's competition here
ALHC vs MOH Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, MOH has a market cap of 11.9B. Regarding current trading prices, ALHC is priced at $23.69, while MOH trades at $227.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas MOH's P/E ratio is 32.94. In terms of profitability, ALHC's ROE is +0.11%, compared to MOH's ROE of +0.04%. Regarding short-term risk, ALHC is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check MOH's competition here
ALHC vs OSCR Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, OSCR has a market cap of 7.4B. Regarding current trading prices, ALHC is priced at $23.69, while OSCR trades at $30.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas OSCR's P/E ratio is -48.36. In terms of profitability, ALHC's ROE is +0.11%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, ALHC is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check OSCR's competition here
ALHC vs CLOV Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, CLOV has a market cap of 2.7B. Regarding current trading prices, ALHC is priced at $23.69, while CLOV trades at $5.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas CLOV's P/E ratio is -43.67. In terms of profitability, ALHC's ROE is +0.11%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, ALHC is more volatile compared to CLOV. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check CLOV's competition here
ALHC vs BHG Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, ALHC is priced at $23.69, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas BHG's P/E ratio is -0.12. In terms of profitability, ALHC's ROE is +0.11%, compared to BHG's ROE of -0.70%. Regarding short-term risk, ALHC is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check BHG's competition here
ALHC vs CABR Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, CABR has a market cap of 18.6M. Regarding current trading prices, ALHC is priced at $23.69, while CABR trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas CABR's P/E ratio is -2.17. In terms of profitability, ALHC's ROE is +0.11%, compared to CABR's ROE of -3.00%. Regarding short-term risk, ALHC is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check CABR's competition here
ALHC vs BMGL Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, BMGL has a market cap of 10.5M. Regarding current trading prices, ALHC is priced at $23.69, while BMGL trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas BMGL's P/E ratio is -1.26. In terms of profitability, ALHC's ROE is +0.11%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, ALHC is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check BMGL's competition here
ALHC vs AET Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, AET has a market cap of 0. Regarding current trading prices, ALHC is priced at $23.69, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas AET's P/E ratio is 9.57. In terms of profitability, ALHC's ROE is +0.11%, compared to AET's ROE of +0.11%. Regarding short-term risk, ALHC is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check AET's competition here
ALHC vs GTS Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, GTS has a market cap of 0. Regarding current trading prices, ALHC is priced at $23.69, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas GTS's P/E ratio is 10.41. In terms of profitability, ALHC's ROE is +0.11%, compared to GTS's ROE of +0.07%. Regarding short-term risk, ALHC is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check GTS's competition here
ALHC vs MGLN Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, ALHC is priced at $23.69, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas MGLN's P/E ratio is 8.49. In terms of profitability, ALHC's ROE is +0.11%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, ALHC is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check MGLN's competition here
ALHC vs UAM Comparison July 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.9B. In comparison, UAM has a market cap of 0. Regarding current trading prices, ALHC is priced at $23.69, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of 264.56, whereas UAM's P/E ratio is 1.01. In terms of profitability, ALHC's ROE is +0.11%, compared to UAM's ROE of +0.17%. Regarding short-term risk, ALHC is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check UAM's competition here